France · Delayed Price · Currency is EUR Sanofi Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw double-digit sales and EPS growth, driven by Dupixent, new launches, and recent acquisitions. Rare disease and vaccine segments posted strong gains, and guidance for high single-digit sales growth in 2026 was reaffirmed. Capital allocation remains focused on core therapeutic areas.
-
Management outlined a strategy for sustained high single- to double-digit growth through 2030, driven by a diversified portfolio, disciplined business development, and strong new launches like Beyfortus and Altuviiio. Key pipeline readouts in immunology and IBD are expected this year.
Fiscal Year 2025
-
Full year 2025 saw 9.9% sales growth, strong Q4 results, and robust launches in medicines and vaccines. Dupixent and ALTUVIIIO drove performance, while strategic acquisitions expanded the vaccines portfolio. 2026 guidance calls for high single-digit sales growth and continued margin expansion.
-
R&D leadership and digital transformation have strengthened the pipeline, with key 2025 approvals for Qfitlia, Wayrilz, and NUVAXOVID. Major advances were made in immunology, rare diseases, oncology, neurology, and vaccines, with over 30 regulatory submissions and 15+ phase III readouts expected by 2027.
-
The session highlighted a strategic shift to an R&D-led model, robust commercial execution, and a focus on pipeline expansion, especially in immunology and specialty care. Margin growth is supported by efficiency gains and divestments, while leadership aims to address industry-wide access and policy challenges.
-
Q3 2025 sales rose 7% year-over-year to €12.4 billion, led by new launches and Dupixent, which surpassed €4 billion in quarterly sales. Guidance for high single-digit sales and low double-digit EPS growth in 2025 was reaffirmed, with strong pipeline progress and disciplined capital allocation.
-
Pipeline progress remains strong with key launches and regulatory milestones, despite setbacks like Itepekimab. Financial guidance will be clarified at Q3, with margins expected to improve and new products driving growth. U.S. policy uncertainty persists, but the company is committed to global access and innovation.
-
Tariffs and U.S. policy remain key uncertainties, but a $20B U.S. investment is planned over 4–5 years. Pipeline confidence is high, with Amlitelimab, Lunsekimig, and Frexalimab seen as future blockbusters. Margin expansion is driven by cost cuts and specialty focus.
-
Q2 2025 saw 10.1% sales growth, led by Dupixent and new launches, with vaccines also performing strongly. Guidance for 2025 was raised to high single-digit sales growth and low double-digit EPS growth, despite flu pricing headwinds and increased R&D investment.
-
The event detailed a refreshed ESG strategy with the AIR program, targeting access, environmental impact, and healthcare system resilience. Highlights included ambitious climate goals, inclusive healthcare initiatives, and a strong focus on diversity and inclusion, with real-world examples of emissions reduction and patient impact.
-
Specialty care is driving growth with assets like dupilumab, Altuviiio, and Sarclisa, supported by recent acquisitions and a robust pipeline. The company is proactively managing regulatory risks and focusing on innovation to offset future revenue challenges, especially as Dupixent approaches LOE.
-
The session highlighted a robust R&D strategy leveraging AI, a diverse immunology pipeline, and strategic acquisitions. Key assets include nanobody-based bispecifics, Amlitelimab, and Duvakitug, with a focus on durable efficacy and innovative mechanisms. AI and partnerships drive future growth.
-
The acquisition expands the rare disease and immunology portfolio, anchored by AYVAKIT and promising pipeline assets. The $9.1B deal, with additional CVRs, is expected to be immediately accretive to margins and drive long-term growth, with integration planned for Q3 2025.
-
The meeting highlighted robust 2024 financial growth, major strategic shifts toward immunology and AI, and the successful carve-out of Opella. All resolutions, including director appointments and a 30th consecutive dividend increase, were strongly approved.
-
Q1 2025 sales rose 9.7% to €9.9B, led by Dupixent and new launches, with gross margin up to 78% and EPS up 15.7%. Guidance is confirmed despite FX and tariff risks, and capital allocation focuses on R&D, buybacks, and dividends. Biologic penetration and pipeline advances support long-term growth.
-
The company has solidified its position as a pure-play biopharma leader, delivering double-digit sales growth and advancing a robust pipeline with multiple blockbuster launches in 2024. Strategic divestments, disciplined capital allocation, and a focus on immunology, neurology, and vaccines underpin strong financial and EPS outlooks for 2025.
Fiscal Year 2024
-
Double-digit sales and EPS growth were driven by new launches, Dupixent, and vaccines, with 2025 guidance projecting continued strong sales and earnings momentum. R&D productivity accelerated, with multiple late-stage pipeline catalysts and a record shareholder return planned for 2025.
-
Q3 sales rose 16% at CER to €13.4B, driven by Dupixent, vaccines, and new launches. 2024 EPS guidance was raised, with strong growth expected in 2025 even after the Opella divestment. Beyfortus and pipeline progress underpin confidence in future performance.
-
Phase III trials showed tolebrutinib significantly reduced disability progression in non-relapsing SPMS and provided a nominal reduction in disability worsening in relapsing MS, despite no difference in relapse rates. Liver enzyme elevations were manageable with enhanced monitoring, and the therapy addresses a major unmet need in SPMS.
-
Double-digit sales growth in Q2 2024 was driven by Dupixent and new launches, leading to an upgraded EPS outlook for 2024. Dupixent surpassed €3 billion in quarterly sales, and Beyfortus is on track for blockbuster status. Robust pipeline progress and disciplined cost management support a positive outlook.
-
Management is focused on delivering 2024–2025 targets, executing the CHC separation, and leveraging a strong pipeline, with Beyfortus and ALTUVIIIO outperforming expectations. R&D investment is rising, cost savings are on track, and key catalysts include tolebrutinib data and CHC progress.